BSE filing, NSE: ASTRAZEN. Summary written from the filing by ALFA Finder's alert engine.
AstraZeneca Pharma India Ltd: key numbers
- Share price
- ₹6,237.00
- Market cap
- ₹15,592 Cr
- Revenue (annual)
- ₹2,276 Cr
- Net profit (annual)
- ₹187.5 Cr
- P/E (TTM)
- 91.9×Sector 46.1×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 2.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from AstraZeneca Pharma India Ltd
All →AstraZeneca Pharma India Capacity Expansion
AstraZeneca Pharma India inaugurated a new corporate office in Mumbai, covering 25,600 sq ft. This expansion strengthens the company's commercial operations and footprint in India.
- office space
- 25600.0 sq ft
AstraZeneca Pharma India Annual General Meeting
AstraZeneca Pharma India Ltd declared the voting results of its postal ballot, confirming the appointment and designation change of certain non-executive directors.
AstraZeneca Pharma India Other Announcement
NSE Sustainability Ratings and Analytics assigned AstraZeneca Pharma India an ESG rating of 73 for FY 2025-26. The rating was independently prepared without company engagement.
AstraZeneca Pharma India Legal & Regulatory
AstraZeneca Pharma India Limited received an order from the ROC, Bengaluru, imposing a total penalty of ₹0.03 Crore for a delayed filing. The company is evaluating next steps.
- Value
- ₹0.03 Cr
- From
- Registrar of Companies, Bengaluru, Karnataka
AstraZeneca Pharma India Legal & Regulatory
AstraZeneca Pharma disclosed a ₹1.88 lakh penalty from the Registrar of Companies due to a delay in filing Form MR-2.
- Value
- ₹0.02 Cr
AstraZeneca Pharma India Management Change
AstraZeneca Pharma India's Dr. Sandeep Arora resigned as Director, Medical Affairs, effective September 15, 2026. The company is seeking a suitable replacement for the position.
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.